DNA and Cell Bank

Since its creation in 1990, the mission of the Genethon’s DNA and Cell Bank is to promote advances in genetic research by providing the scientific community with a high quality cell and human tissue products resource.

Europe’s leading bank for genetic diseases, it serves the whole of the medical and scientific community.


Each year, Genethon’s DNA and Cell Bank:

  • Produces approximately 2,000 lymphoblastoid cell lines
  • Performs approximately 3,000 DNA extractions
  • Prepares primary myoblast and fibroblast cultures from approximately 100 biopsies

It has a total storage capacity of 436,000 samples.

Breakdown of pathologies contained in the Genethon DNA and Cell bank

Management & Traceability

Genethon has developed a computer database for ensuring sample management and traceability, which has been submitted to and approved by the CNIL. The Genethon DNA and Cell Bank has been AFNOR certified, according to French biological research center standard NF S 96-900.

Biological resource collection and transportation guidelines and Charter

A charter has been drawn up to govern relationships between the DNA and Cell Bank and any persons using its services, in accordance both with ethical guidelines for the collection of human products, laws and regulations governing the collection of samples, their treatment and storage, and all related provisions.

The DNA and Cell Bank complies with specific guidelines regarding the collection and transportation of biological resources.


The Genethon DNA and Cell Bank is an IBiSA platform:

  • INSERM (French National Healthcare and Medical Research Institute)
  • CNRS (French National Center for Scientific Research)
  • Patient associations (Rett syndrome, Fondation Vaincre l’Autisme etc.)
  • Neuromuscular disease research networks supported by AFM
  • Cancer centers (Curie, Gustave Roussy and René Huguenin institutes)
  • Partnerships with scientists and institutions from countries in the Mediterranean basin (Algeria, Tunisia, Morocco, Turkey, Lebanon, Syria, Iran and Saudi Arabia) researching rare diseases
  • Participation in European projects: ECRAF (European Consortium on Rheumatoid Arthritis Families), EuroAs (European research project on ankylosing spondylitis), EuroBioBank (European network of biological banks for research into rare diseases), BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) and Treat-NMD.